Skip to content
Screener

Accrued Litigation at other companies

Perpetua Resources Corp. logo
Perpetua Resources Corp.PPTA
$1M-50.0%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$41M-86.2%
Janus Living logo
Janus LivingJAN
$660K+1,220%
Getty Images logo
Getty ImagesGETY
$208.4M+85.4%
Momentus logo
MomentusMNTS
$2.06M+391%
Ampco-Pittsburgh logo
Ampco-PittsburghAP
$164.97M-6.4%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.57B+66.5%
Enterprise value$4.9B+88.6%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemMarch 31, 2026December 31, 2025
Income taxes payable262
Total current liabilities779914
Long-term debt, less current portion486290
Accrued litigation settlement expenses, noncurrent4152
Operating lease liabilities, noncurrent1422
Other noncurrent liabilities2121
Total liabilities$1,341$1,300
Commitments and contingencies (Note 12)

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s accrued litigation?
Indivior Pharmaceuticals, Inc. (INDV) reported accrued litigation of $41M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s accrued litigation changed year-over-year?
Indivior Pharmaceuticals, Inc.'s accrued litigation decreased by 86.2% year-over-year, from $297M to $41M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s accrued litigation?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s accrued litigation has grown at a -61.9% compound annual growth rate (CAGR), from $359M to $52M.
What does accrued litigation mean?
This liability represents the estimated financial impact of ongoing legal proceedings, settlements, or regulatory investigations. It reflects management's best estimate of the costs required to resolve legal disputes that are considered probable and estimable. High or increasing balances in this category indicate significant legal risk and potential future cash outflows that could impact the company's financial stability.

Ask your AI about Indivior Pharmaceuticals, Inc.'s accrued litigation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude